Why the study?
Does extended-release acetylsalicylic acid provide sustained 24-hour anti-thrombotic coverage compared to immediate-release formulations in patients requiring secondary prevention?
Does extended-release acetylsalicylic acid provide sustained 24-hour anti-thrombotic coverage compared to immediate-release formulations in patients requiring secondary prevention?
Extended-release aspirin formulations may overcome the limitations of traditional immediate-release aspirin by providing sustained 24-hour antiplatelet coverage for secondary cardiovascular prevention.
Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period.
No takes yet. Share an insight, caveat, or question.
Bliden et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: